Zymeworks Inc Registered Shs ZYME
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
-
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
-
Zymeworks Gets FDA Fast-Track Designation for ZW191 in Ovarian Cancer
-
Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment
-
Zymeworks Shares Climb After FDA Clears Investigational New Drug Application
Trading Information
- Previous Close Price
- $24.19
- Day Range
- $24.01–24.59
- 52-Week Range
- $11.51–29.75
- Bid/Ask
- $22.28 / $26.80
- Shares Outstanding
- 73.57M
- Market Cap
- $1.78B
- Volume/Avg
- 444,694 / 655,664
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.06%
Company Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 264
- Website
- https://www.zymeworks.com
Valuation
|
Metric
|
ZYME
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.89 |
Price/Sales | 22.41 |
Price/Cash Flow | — |
Price/Earnings
ZYME
Financial Strength
|
Metric
|
ZYME
|
|---|---|
Quick Ratio | 10.36 |
Current Ratio | 10.82 |
Interest Coverage | — |
Quick Ratio
ZYME
Profitability
|
Metric
|
ZYME
|
|---|---|
Return on Assets (Normalized) | −18.05% |
Return on Equity (Normalized) | −26.29% |
Return on Invested Capital (Normalized) | −28.16% |
Return on Assets
ZYME
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&vtcL>y | LOCK|#R$Cv | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|JR@WGy | LOCK|?Fx#R | $71B | |||
| argenx SE ADR
ARGX
| LOCK|kBFNw^% | LOCK|n$< | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|N?#&$T | LOCK|J!< | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Bq&S$>$ | LOCK|@>&j | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#Y&>mw> | LOCK|yKmx | $26B | |||
| Moderna Inc
MRNA
| LOCK|t<mq$RR | LOCK|&$V | $25B | |||
| Incyte Corp
INCY
| LOCK|cKZnG&< | LOCK|nf< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%xLh!S? | LOCK|V!d | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!fVSw^ | LOCK|Kq | $16B |
United States